Fresenius Medical Care Accelerates Second Tranche of €1 Billion Share Buyback

Fresenius Medical Care ( (FMS) ) has provided an announcement.

On January 9, 2026, Fresenius Medical Care AG announced it will continue its EUR 1 billion share buyback program, originally unveiled in June 2025, by launching a second tranche after completing the first tranche ahead of schedule on December 29, 2025. Under the new tranche, the company plans to repurchase approximately EUR 415 million of its own shares on the stock exchange between January 12 and May 8, 2026, with the intention of predominantly redeeming the shares and using a smaller portion for incentive-based compensation, thereby accelerating completion of the overall buyback authorized by shareholders at the May 20, 2021 Annual General Meeting.

The most recent analyst rating on (FMS) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Fresenius Medical Care stock, see the FMS Stock Forecast page.

Spark’s Take on FMS Stock

According to Spark, TipRanks’ AI Analyst, FMS is a Neutral.

Fresenius Medical Care’s overall score is driven by strong earnings call performance and fair valuation, offset by technical analysis indicating bearish trends and financial performance challenges. The company’s strategic initiatives and share buyback program are positive, but operational and market challenges remain.

To see Spark’s full report on FMS stock, click here.

More about Fresenius Medical Care

Fresenius Medical Care AG is a German-based healthcare company specializing in dialysis products and services for patients with chronic kidney failure. Operating globally, it provides dialysis machines, related disposables, and clinical services, with a core focus on serving healthcare systems and patients requiring renal replacement therapies.

Average Trading Volume: 451,585

Technical Sentiment Signal: Sell

Current Market Cap: $13.38B

Learn more about FMS stock on TipRanks’ Stock Analysis page.